Immunic Inc
IMUX0.950USD
+0.019+2.02%
Horário de mercado （ET）Cotações atrasadas em 15 min
85.67MValor de mercado
PerdaP/L TTM
Mais detalhes de Immunic Inc Empresa
Immunic, Inc. is a biotechnology company. The Company is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Company’s s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase II clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease. IMU-381 is in preclinical testing, a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.
Informações da empresa
Código da empresaIMUX
Nome da EmpresaImmunic Inc
Data de listagemApr 17, 2014
CEODr. Daniel Vitt, Ph.D.
Número de funcionários91
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 17
Endereço1200 Avenue Of The Americas
CidadeNEW YORK
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal10036
Telefone13322559818
Sitehttps://imux.com/
Código da empresaIMUX
Data de listagemApr 17, 2014
CEODr. Daniel Vitt, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Daniel Vitt, Ph.D.
Dr. Daniel Vitt, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
391.88K
+3.98%
Dr. Joerg Neermann, Ph.D.
Dr. Joerg Neermann, Ph.D.
Independent Director
Independent Director
200.00K
+100.00%
Mr. Glenn Whaley, CPA
Mr. Glenn Whaley, CPA
Chief Financial Officer
Chief Financial Officer
95.51K
+89.09%
Dr. Duane D. Nash, M.D.
Dr. Duane D. Nash, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
42.03K
+90.78%
Mr. Jason Tardio
Mr. Jason Tardio
President, Chief Operating Officer
President, Chief Operating Officer
12.51K
--
Ms. Simona Skerjanec, M.D.
Ms. Simona Skerjanec, M.D.
Independent Director
Independent Director
--
--
Dr. Andreas Muehler, M.D.
Dr. Andreas Muehler, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Inderpal Singh
Mr. Inderpal Singh
General Counsel
General Counsel
--
--
Ms. Maria Toernsen
Ms. Maria Toernsen
Independent Director
Independent Director
--
--
Dr. Hella Kohlhof, Ph.D.
Dr. Hella Kohlhof, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Daniel Vitt, Ph.D.
Dr. Daniel Vitt, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
391.88K
+3.98%
Dr. Joerg Neermann, Ph.D.
Dr. Joerg Neermann, Ph.D.
Independent Director
Independent Director
200.00K
+100.00%
Mr. Glenn Whaley, CPA
Mr. Glenn Whaley, CPA
Chief Financial Officer
Chief Financial Officer
95.51K
+89.09%
Dr. Duane D. Nash, M.D.
Dr. Duane D. Nash, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
42.03K
+90.78%
Mr. Jason Tardio
Mr. Jason Tardio
President, Chief Operating Officer
President, Chief Operating Officer
12.51K
--
Ms. Simona Skerjanec, M.D.
Ms. Simona Skerjanec, M.D.
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BVF Partners L.P.
9.29%
abrdn Inc.
8.60%
Soleus Capital Management, L.P.
7.61%
Avidity Partners Management LP
4.65%
The Vanguard Group, Inc.
4.10%
Other
65.74%
Investidores
Investidores
Proporção
BVF Partners L.P.
9.29%
abrdn Inc.
8.60%
Soleus Capital Management, L.P.
7.61%
Avidity Partners Management LP
4.65%
The Vanguard Group, Inc.
4.10%
Other
65.74%
Tipos de investidores
Investidores
Proporção
Hedge Fund
26.20%
Investment Advisor
13.30%
Investment Advisor/Hedge Fund
11.31%
Individual Investor
1.36%
Research Firm
1.05%
Pension Fund
0.06%
Other
46.74%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
135
51.29M
53.53%
-8.04M
2025Q1
143
43.91M
45.87%
-16.90M
2024Q4
141
54.47M
60.46%
-15.06M
2024Q3
152
61.42M
68.19%
-8.79M
2024Q2
169
63.34M
74.84%
-9.30M
2024Q1
202
64.86M
76.52%
-3.93M
2023Q4
199
22.30M
46.89%
-13.27M
2023Q3
205
25.26M
53.96%
-11.93M
2023Q2
209
27.09M
58.47%
-12.08M
2023Q1
208
31.66M
68.86%
-6.82M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BVF Partners L.P.
8.90M
9.29%
--
--
Mar 31, 2025
abrdn Inc.
1.06M
1.11%
+1.06M
--
Mar 31, 2025
Soleus Capital Management, L.P.
7.29M
7.61%
--
--
Mar 31, 2025
Avidity Partners Management LP
4.45M
4.65%
-3.51M
-44.09%
Mar 31, 2025
The Vanguard Group, Inc.
3.93M
4.1%
+7.79K
+0.20%
Mar 31, 2025
Focus Partners Wealth, LLC
2.58M
2.7%
+415.10K
+19.14%
Mar 31, 2025
Gratus Capital LLC
2.11M
2.2%
+56.86K
+2.77%
Jun 30, 2024
Omega Fund Management, LLC
1.79M
1.87%
--
--
Mar 31, 2025
Adage Capital Management, L.P.
1.40M
1.46%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
976.15K
1.02%
+23.86K
+2.51%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Micro-Cap ETF
0.02%
Invesco NASDAQ Future Gen 200 ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Proporção0.02%
Invesco NASDAQ Future Gen 200 ETF
Proporção0%
Avantis US Small Cap Equity ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
